BLOOMBERG: Actavis Near $64B Deal for Allergan

  

Actavis is close to a deal to buy Allergan Inc. for more than $64B in a transaction that would help the maker of Botox rebuff a hostile advance from Valeant Pharmaceuticals. Bloomberg’s Caroline Hyde Reports on “Countdown.”